Skip to main content
main-content

ESMO 2019

Free registration

Medicine Matters is developed for healthcare professionals as

a premier resource for the latest clinical information in medicine.

ESMO Congress 2019 coverage

All the breaking news and expert interviews from the meeting in Barcelona (September 27–1 October 2019).


Featured trials


Genitourinary cancers

Expert interviews

07-10-2019 | Prostate cancer | Video | Article

Expert comment: The STAMPEDE study

Eleni Efstathiou shares her views on the STAMPEDE analysis indicating that docetaxel may be an option for hormone-naïve prostate cancer regardless of metastatic disease burden (2:16).

07-10-2019 | Renal cell carcinoma | Video | Article

Researcher comment: A novel CXCR4 inhibitor for RCC and a novel immunotherapy endpoint

David McDermott talks through his renal cell carcinoma research exploring the use of a novel oral CXCR4 inhibitor and treatment-free survival as an alternative endpoint for immunotherapy trials (4:03).

This independent video interview was supported by an educational grant from Pfizer and Merck KGaA

04-10-2019 | Castration-resistant prostate cancer | Video | Article

Researcher comment: Cabazitaxel a new third-line option in mCRPC

Ronald de Wit tells us why the CARD trial results are likely to change the paradigm for the treatment of metastatic castration-resistant prostate cancer (3:58).

04-10-2019 | Renal cell carcinoma | Video | Article

Expert highlights: RCC immunotherapy at ESMO 2019

Axel Merseburger presents his round-up of the most interesting research on immunotherapy in renal cell carcinoma at the ESMO Congress 2019, including the TITAN RCC study and additional analyses from JAVELIN Renal 101 (3:14).

This independent video interview was supported by an educational grant from Pfizer and Merck KGaA

03-10-2019 | Castration-resistant prostate cancer | Video | Article

Researcher comment: PROfound improvement in outcomes with olaparib in mCRPC

The PROfound trial evaluated olaparib in metastatic castration-resistant prostate cancer ─ Maha Hussain discusses the clinical implications and practical applications of the findings (2:40).

02-10-2019 | Castration-resistant prostate cancer | Video | Article

Expert comment: The CARD trial

Silke Gillessen comments on the phase IV CARD study investigating third-line cabazitaxel in men with metastatic castration-resistant prostate cancer (3:02). 

02-10-2019 | Castration-resistant prostate cancer | Video | Article

Expert comment: The PROfound trial

Eleni Efstathiou explains why the PROfound trial of the PARP inhibitor olaparib is the first step towards treating metastatic castration-resistant prostate cancer in a more precise way (3:09).

02-10-2019 | Genitourinary cancers | Video | Article

Expert highlights: Genitourinary cancers at ESMO 2019

Axel Merseburger takes us through his top picks of the genitourinary cancer research reported at the ESMO Congress 2019, including updates on the TITAN and STAMPEDE prostate cancer trials, the SORCE trial in renal cell carcinoma, and the investigation of first-line enfortumab vedotin in bladder cancer (5:33).

01-10-2019 | Renal cell carcinoma | ESMO 2019 | Article

Researcher comment: JAVELIN Renal 101 – combination approach for advanced RCC patients without upfront cytoreductive nephrectomy

Laurence Albiges discusses a JAVELIN Renal 101 subgroup analysis indicating that avelumab plus axitinib achieves tumor reduction in patients with metastatic renal cell carcinoma (2:30).

This independent video interview was supported by an educational grant from Pfizer and Merck KGaA

30-09-2019 | Renal cell carcinoma | Video | Article

Researcher comment: TITAN-RCC findings show efficacy of tailored immunotherapy approach

Marc-Oliver Grimm talks through the results of the tailored nivolumab plus boost ipilimumab approach used in the TITAN-RCC study (3:38).

This independent video interview was supported by an educational grant from Pfizer and Merck KGaA

30-09-2019 | Urothelial cancer | Video | Article

Researcher comment: IMvigor130 trial of atezolizumab in advanced urothelial cancer

Enrique Grande tells us why the IMvigor130 data, although very promising, are not quite ready for translation to the clinic yet (1:43).

30-09-2019 | Renal cell carcinoma | Video | Article

Expert comment: RCC immunotherapy – biomarker round-up

Guillermo de Velasco discusses four posters presented at the ESMO Congress 2019 focusing on biomarker analyses of the ADAPTeR, JAVELIN Renal 101 and NIVOREN GETUG-AFU 26 trials (6:07).

This independent video interview was supported by an educational grant from Pfizer and Merck KGaA

Research news

22-10-2019 | Renal cell carcinoma | ESMO 2019 | News

Benefit of nivolumab–tivozanib, nivolumab beyond progression shown in metastatic RCC

Studies presented at the ESMO 2019 Congress propose that patients with metastatic renal cell carcinoma may benefit from a combination of nivolumab and the VEGFR tyrosine kinase inhibitor tivozanib, or by continuing with single-agent nivolumab past initial disease progression.

21-10-2019 | Renal cell carcinoma | ESMO 2019 | News

Treatment-free survival proposed as novel RCC immunotherapy endpoint

Time spent off treatment could be used as a novel clinical trial endpoint for patients undergoing renal cell carcinoma immunotherapy, suggest study findings reported at the ESMO Congress 2019 in Barcelona, Spain.

18-10-2019 | Renal cell carcinoma | ESMO 2019 | News

KEYNOTE-427 updates confirm pembrolizumab benefit for advanced RCC

The latest findings from the KEYNOTE-427 trial add to the efficacy evidence for first-line pembrolizumab against advanced or metastatic renal cell carcinoma regardless of histology.


Lung and thoracic cancers

Expert interviews

04-10-2019 | Non-small cell lung cancer | Video | Article

Expert comment: The CheckMate 227 study

Sanjay Popat brings context to the CheckMate 227 data in light of the currently available options for patients with treatment-naïve, advanced non-small-cell lung cancer, highlighting the key aspects physicians need to bear in mind when considering nivolumab­ plus ipilimumab for their patients (2:20).

03-10-2019 | Non-small cell lung cancer | Video | Article

Expert comment: Brain metastases in lung cancer

Lizza Hendriks provides insight into two studies focusing on brain metastases in patients with non-small-cell lung cancer, the ASCEND-7 trial of ceritinib and an analysis of the genomic and epigenomic landscape of the metastases (4:26).

02-10-2019 | Non-small cell lung cancer | Video | Article

Expert highlights: Lung and thoracic cancers at ESMO 2019

Ross Camidge comments on the advanced non-small-cell lung cancer research that caught his attention at the ESMO Congress 2019, including the FLAURA and CheckMate 227 overall survival data, and updates on brigatinib and lorlatinib (3:01).

01-10-2019 | Non-small cell lung cancer | Video | Article

Researcher comment: Take-home messages from the CheckMate 227 trial

Solange Peters discusses the implications of the CheckMate 227 findings for the front-line treatment of advanced non-small-cell lung cancer and outlines the key next steps (3:45).

01-10-2019 | Mesothelioma | Video | Article

Researcher comment: PROMISE-meso trial fails to meet primary endpoint

Sanjay Popat reports on the trial pitting pembrolizumab against chemotherapy in relapsed malignant pleural mesothelioma and outlines possible strategies for taking immune checkpoint inhibitors forward (4:53). 

29-09-2019 | Non-small cell lung cancer | Video | Article

Researcher comment: Positive OS data for osimertinib in FLAURA trial

Suresh Ramalingam presents the overall survival analysis of the FLAURA trial of osimertinib in EGFR mutation-positive, advanced non-small-cell lung cancer, and discusses the options after progression on the tyrosine kinase inhibitor (1:50).

Research news

15-10-2019 | Non-small cell lung cancer | ESMO 2019 | News

Value of blood-based screening for ALK fusions shown in patients with NSCLC

Blood-based next-generation sequencing can be used to identify patients with non-small-cell lung cancer and ALK fusions who will benefit from treatment with alectinib, show results of the phase II/III blood-first assay screening trial.

11-10-2019 | Non-small cell lung cancer | ESMO 2019 | News

IMpower110: OS boost with first-line atezolizumab in PD-L1-high metastatic NSCLC

An interim analysis of the IMpower110 study has demonstrated an overall survival improvement with atezolizumab versus chemotherapy in treatment-naïve patients with stage IV non-small-cell lung cancer and high levels of PD-L1 expression.

10-10-2019 | Non-small cell lung cancer | ESMO 2019 | News

​​​​​​​Nivolumab–ipilimumab an option for untreated, advanced NSCLC regardless of PD-L1 levels

Individuals with advanced non-small-cell lung cancer derive an overall survival benefit from first-line treatment with nivolumab plus ipilimumab irrespective of PD-L1 expression, report the CheckMate 227 investigators.


Reference

ESMO 2019 key clinical trial overviews

Read concise summaries of the practice-changing clinical trials being presented at ESMO 2019 in the areas of genitourinary cancers and thoracic cancers. Highlights include CARD, PROfound, and IMvigor130, as well as IMpower110, CheckMate 227, and FLAURA.

Image Credits